Categories
Colon Cancer

Adding chemotherapy to immunotherapy in metastatic CRC [Video]

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents data from the phase Ib KEYNOTE-651 trial (NCT03374254), which assessed pembrolizumab with modified FOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer (mCRC). In two out of five cohorts, patients with microsatellite stable CRC were given first- or second-line pembrolizumab with modified FOLFOX7 or FOLFIRI and the progression-free survival (PFS) was found to be comparable to that of patients not receiving pembrolizumab. Dr Kim additionally discusses the efficacy of certain biomarkers such as PD-L1 levels and the mutational status of KRAS in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Pancreatic Cancer

Second-line treatment strategies for pancreatic cancer [Video]

Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, gives an overview of treatment options for patients who progress on first-line treatments for pancreatic cancer including taxane-based chemotherapy and gemcitabine. Oxaliplatin and 5-fluorouracil as part of FOLFOX as well as liposomal irinotecan (nal-IRI) are typically administered when patients progress from the current first-line treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Pancreatic Cancer

SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer [Video]

Whilst nab-paclitaxel and gemcitabine are prescribed for patients with basal subtype of metastatic pancreatic cancer, FOLFIRINOX is the standard of care for patients with the classic subtype. Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, discusses findings from the phase I SEQUENCE trial (NCT02504333) of nab-paclitaxel and gemcitabine followed by modified FOLFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients received the investigatory regimen over a six week period as first line treatment and a superior median overall survival (OS) rate was reported in receiving the novel combination. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.